Brief news reports on Tuberculosis

Obama’s global, domestic & HIV research FY 2013 budget backslides on existing commitments

Treatment Action Group (TAG) is deeply disappointed by President Obama’s proposed cuts to PEPFAR (President’s Emergency Plan for AIDS Relief) and bilateral TB funds, freezing of NIH (National Institutes of Health) research as well as the insufficient attention to the worsening domestic AIDS crisis in the administration's fiscal year 2013 budget plan.

Read More →

CDC at the frontlines of TB research in Kenya: a conversation with Kayla Laserson

This is the first in a series of conversations with officials at the Centers for Disease Control and Prevention (CDC), discussing the CDC’s role in global HIV and tuberculosis research and development.  The following interview is with Kayla Laserson, Director of the Kenya Medical Research Institute (KEMRI)/CDC Field Research Station in Kisumu, Kenya. Dr. Laserson oversees a staff of over 950 individuals and a comprehensive research program in HIV, malaria, TB, emerging infectious diseases, demographic surveillance, and programmatic service delivery of HIV care, treatment and prevention programs. 

Read More →

Nanologica becomes a strategic partner in €10M EU project to develop new treatments for tuberculosis

Nanologica leverages its carrier materials to play a key part in the four-year EU project, ORCHID. Led by GlaxoSmithKline (GSK), the €10 million project aims to discover and develop new medicines against multiple drug resistant tuberculosis.

Read More →

Getting to zero – elements of a TB elimination campaign for leaders to endorse and implement

We need a new vision for TB writes AIDS and TB activist Mark Harrington, Executive Director of the Treatment Action Group.

Read More →

PEPFAR raided to meet Global Fund pledge in President Obama’s fiscal year 2013 budget

The Obama Administration released its fiscal year 2013 budget today with a proposed $1.65 billion funding level—an increase of 26.9 percent – for the Global Fund to Fight AIDS, Tuberculosis and Malaria to meet the US pledge of $4 billion over 3 years.  This substantial and welcome budget request for the Global fund clearly came at the expense of PEPFAR, the U.S.’s flagship bilateral program which is slated for a stunning cut of $542.9 million—a reduction of almost 13 percent.   Global tuberculosis also saw a reduction of 10 percent, with a proposed budget request of $224 million compared to this year’s budget of $249 million.  On a more upbeat note, the President’s budget would restore language allowing the use of federal funds for lifesaving syringe exchange programs to reduce HIV and hepatitis transmission among injection drug users.

Read More →

Need for expanded access to two promising MDR TB drugs

Two experimental drugs for the treatment of MDR TB have completed phase II clinical trials.

Read More →

Avesthagen, CosmosID ink pact for diagnosis of TB

Bangalore, February 8, 2012: Avesthagen Limited – India’s leading sytems biology biotechnology company, has signed a MOU with CosmosID™, a U.S. based company for collaborating to correctly diagnose and therapeutically manage Tuberculosis treatment.

Read More →

South Africa: MDR-TB trials could make a tangible difference for children

A team from Stellenbosch University's Desmond Tutu TB Centre will be monitoring 200 children at the Brooklyn Chest Hospital in Cape Town over the next five years in a potentially groundbreaking trial.

Read More →

Gates Foundation invests in cutting-edge research to diagnose tuberculosis in developing countries

The Bill & Melinda Gates Foundation today announced $7.7 million in funding for 10 new grants to identify biomarkers for diagnosing tuberculosis (TB) in low-resource settings.

Read More →

Europe: Management of TB cases falls short of international standards

The management of tuberculosis cases in the European Union (EU) is not meeting international standards, according to new research.

Read More →

Page 503 of 540 · Total posts: 10

←First 502 503 504 Last→